{"disease":{"id":"cluster-headache-syndrome","name":"Cluster headache syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"caffeine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ergot","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ergot","company_name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"phenobarbitone","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dihydroergotamine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migranal","generic_name":"DIHYDROERGOTAMINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Ergotamine Derivative","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sumatriptan","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imitrex","generic_name":"SUMATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":80,"revenue":null,"mechanism":"Imitrex works by binding to serotonin receptors in the brain, specifically the 5-HT1D subtype, to constrict blood vessels and block pain pathways."},{"drug_id":"ergotamine","indication_name":"Cluster headache syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migergot","generic_name":"ERGOTAMINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04845451","title":"The Presence and Role of Zygomatic-temporal Neuroma Triggering Cluster Headache","phase":"","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"FARO T. OWIESY, M.D","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}